Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Tolaney, Sara M, Wardley, Andrew M, Zambelli, Stefania, Hilton, John F, Troso-Sandoval, Tiffany A, Ricci, Francesco, Im, Seock-Ah, Kim, Sung-Bae, Johnston, Stephen RD, Chan, Arlene, Goel, Shom, Catron, Kristen, Chapman, Sonya C, Price, Gregory L, Yang, Zhengyu, Gainford, M Corona, André, Fabrice
Published in The lancet oncology (01.06.2020)
Published in The lancet oncology (01.06.2020)
Get full text
Journal Article
Abstract P3-11-10: Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer
Tolaney, Sara M, Wardley, Andrew M, Zambelli, Stefania, Hilton, John F., Troso-Sandoval, Tiffany A, Ricci, Francesco, Im, Seock-Ah, Kim, Sung-Bae, Johnston, Stephen RD, Chan, Arlene, Goel, Shom, Catron, Kristen, Yang, Zhengyu, Gianford, M. Corona, Price, Gregory L, André, Fabrice
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article